Hematopoietic cell transplantation for Chediak-Higashi syndrome

Bone Marrow Transplantation

Volumn 39, Issue 7, 2007, Pages 411-415

  Eapen, M ^a   DeLaat, C A ^b   Baker, K S ^c   Cairo, M S ^d   Cowan, M J ^e   Kurtzberg, J ^f   Steward, C G ^g   Veys, P A ^h   Filipovich, A H ^b  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^d Och Spine at New York Presbyterian Hospitals   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

^g BRISTOL ROYAL HOSPITAL FOR CHILDREN   (United Kingdom)

^h GREAT ORMOND STREET HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; BUSULFAN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; ETOPOSIDE; IMMUNOGLOBULIN; METHOTREXATE; THYMOCYTE ANTIBODY;

ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CHEDIAK HIGASHI SYNDROME; CHILD; CLINICAL ARTICLE; DISEASE COURSE; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HEMATOLOGIC DISEASE; HLA MATCHING; HUMAN; IMMUNOPATHOLOGY; LIVING DONOR; MALE; MORTALITY; MYELODYSPLASTIC SYNDROME; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROBABILITY; RETROSPECTIVE STUDY; REVIEW; T CELL DEPLETION; WHOLE BODY RADIATION;

ADOLESCENT; CHEDIAK-HIGASHI SYNDROME; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HLA ANTIGENS; HUMANS; MALE; RETROSPECTIVE STUDIES; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 33947625671     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705600     Document Type: Review

References (19)

1. Barak Y, Nir E. Chediak-Higashi syndrome. Am J Pediatr Hematol Oncol 1987; 9: 42-55.
2. Pettit RE, Berdal KG. Chediak-Higashi syndrome. Neurologic appearance. Arch Neurol 1984; 41: 1001-1002.
3. Grossi CE, Crist WM, Abo T, Velardi A, Cooper MD. Expression of the Chediak-Higashi lysosomal abnormality in human peripheral blood lymphocyte subpopulations. Blood 1985; 65: 837-844.
4. Certain S, Barrat F, Pastural E, Le Deist F, Goyo-Rivas J, Jabado N et al. Protein truncation test of LYST reveals heterogenous mutations in patients with Chediak-Higashi syndrome. Blood 2000; 95: 979-983.
5. Zarzour W, Kleta R, Frangoul H, Suwannarat P, Jeong A, Kim SY et al. Two novel CHS1 (LYST) mutations: Clinical correlations in an infant with Chediak-Higashi syndrome. Mol Genet Metab 2005; 85: 125-132.
6. Davis WC, Douglas SD. Defective granule formation and function in the Chediak-Higashi syndrome in man and animals. Semin Hematol 1972; 9: 431-450.
7. Abo T, Roder JC, Abo W, Cooper MD, Balch CM. Natural killer (HNK-1 +) cells in Chediak-Higashi patients are present in normal numbers but are abnormal in function and morphology. J Clin Invest 1982; 70: 193-197.
8. Rubin CM, Burke BA, McKenna RW, McClain KL, White JG, Nesbit ME et al. The accelerated phase of Chediak-Higashi syndrome. An expression of the virus-associated hemophagocytic syndrome? Cancer 1985; 56: 524-530.
9. Aslan Y, Erduran E, Gedik Y, Mocan H, Yildiran A. The role of high dose methylprednisolone and splenectomy in the accelerated phase of Chediak-Higashi syndrome. Acta Haematol 1996; 96: 105-107.
10. Fukuda M, Morimoto T, Ishida Y, Suzuki Y, Murakami Y, Kida K et al. Improvement of peripheral neuropathy with oral prednisolone in Chediak-Higashi syndrome. Eur J Pediatr 2000; 159: 300-301.
11. Filipovich AH, Shapiro RS, Ramsay NK, Kim T, Blazar B, Kersey J et al. Unrelated donor bone marrow transplantation for correction of lethal congenital immunodeficiencies. Blood 1992; 80: 270-276.
12. Fischer A, Landais P, Friedrich W, Gerritsen B, Fasth A, Porta F et al. Bone marrow transplantation (BMT) in Europe for primary immunodeficiencies other than severe combined immunodeficiency: A report from the European Group for BMT and the European Group for Immunodeficiency. Blood 1994; 83: 1149-1154.
13. Diamond HR, Souza MH, Silva ML, Tabak DG, Ferman S, M-Silva VM et al. Natural killer cell activity in a patient with Chediak-Higashi syndrome submitted to bone marrow transplantation. Pediatr Hematol Oncol 1995; 12: 399-402.
14. Mottonen M, Lanning M, Saarinen UM. Allogeneic bone marrow transplantation in Chediak-Higashi syndrome. Pediatr Hematol Oncol 1995; 12: 55-59.
15. Haddad E, Le Deist F, Blanche S, Benkerrou M, Rohrlich P, Vilmer E et al. Treatment of Chediak-Higashi syndrome by allogenic bone marrow transplantation: Report of 10 cases. Blood 1995; 85: 3328-3333.
16. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825-828.
17. Flowers ME, Kansu E, Sullivan KM. Pathophysiology and treatment of graft-versus-host disease. Hematol Oncol Clin North Am 1999; 13: 1091-1112, viii-ix.
18. Klein JP, Moeschberger ML. Survival Analysis: Techniques of Censored and Truncated Data. Springer-Verlag: Berlin, 2003.
19. Tardieu M, Lacroix C, Neven B, Bordigoni P, de Saint Basile G, Blanche S et al. Progressive neurologic dysfunctions 20 years after allogeneic bone marrow transplantation for Chediak-Higashi syndrome. Blood 2005; 106: 40-42.